SAGE - Sage Therapeutics, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD
162.285
+0.195 (+0.12%)
As of 9:35AM EDT. Market open.
Stock chart is not supported by your current browser
Previous close162.090
Open162.870
Bid160.020 x 900
Ask167.160 x 1200
Day's range162.240 - 163.922
52-week range59.570 - 195.970
Volume7,066
Avg. volume489,773
Market cap7.549B
Beta3.70
PE ratio (TTM)N/A
EPS (TTM)-7.223
Earnings date7 Aug 2017 - 11 Aug 2017
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est206.79
Trade prices are not sourced from all markets
  • SAGE Therapeutics’ NMDA Receptor–Based Portfolio
    Market Realist2 days ago

    SAGE Therapeutics’ NMDA Receptor–Based Portfolio

    As discussed, SAGE Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system disorders.

  • SAGE Therapeutics’ GABA Receptor–Based Portfolio
    Market Realist2 days ago

    SAGE Therapeutics’ GABA Receptor–Based Portfolio

    As we discussed earlier, SAGE Therapeutics’ (SAGE) portfolio includes the products it has under development for the treatment of life-threatening central nervous system disorders based on either GABA (gamma-Aminobutyric acid) or NMDA (N-methyl-D-aspartate) receptor systems.

  • A Look at SAGE Therapeutics’ Product Portfolio
    Market Realist5 days ago

    A Look at SAGE Therapeutics’ Product Portfolio

    SAGE Therapeutics (SAGE) includes two different programs based on the modulation of GABAA (gamma-Aminobutyric acid) and NMDA (N-methyl-D-aspartate) receptors for the treatment of life-threatening central nervous system disorders. Let’s have a look at the details of these programs.

  • SAGE Therapeutics’ Strategic Collaboration with Shionogi
    Market Realist5 days ago

    SAGE Therapeutics’ Strategic Collaboration with Shionogi

    On June 13, SAGE Therapeutics (SAGE) announced a strategic collaboration with Shionogi & Company for the development and commercialization of the drug SAGE-217. Let’s take a look at the details of the collaboration.

  • SAGE Therapeutics’ Stock Performance and Estimates in June
    Market Realist5 days ago

    SAGE Therapeutics’ Stock Performance and Estimates in June

    SAGE Therapeutics (SAGE), a clinical research–based biopharmaceutical company, develops drugs for the treatment of life-threatening central nervous system disorders such as Parkinson’s disease and postpartum depression.

  • MarketWatch6 days ago

    Sage shares drop 3% after $90 mln Shionogi deal for key drug

    Sage Therapeutics Inc. shares dropped 3.3% in Thursday morning trade after the company announced a $90 million deal with Shionogi & Co. Ltd. for the clinical development and commercialization of its drug SAGE-217 in Japan, Taiwan and South Korea. Shionogi will also handle clinical development, regulatory filings and commercialization of SAGE-217 for major depressive disorder and any other indications in those countries.

  • Business Wire6 days ago

    Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, and Shionogi & Co., Ltd., today announced they have entered into a strategic collaboration for the clinical development and commercialization of SAGE-217 for the treatment of major depressive disorder (MDD) and other indications in Japan, Taiwan and South Korea. Sage received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for SAGE-217 in MDD in February 2018, and recently announced an expedited development plan for SAGE-217 in the U.S. with a pivotal Phase 3 placebo-controlled trial in patients with MDD expected to commence this year, and an ongoing placebo-controlled trial in women with PPD, now also designated a pivotal trial.

  • Biotech Stock Loses Steam, But Analysts Still Bullish On Depression Drug
    Investor's Business Daily7 days ago

    Biotech Stock Loses Steam, But Analysts Still Bullish On Depression Drug

    Sage Therapeutics lost some of its steam Wednesday, as shares dropped more than 3%, but analysts remained bullish on the biotech company's plans for an acute depression treatment.

  • Company News For Jun 13, 2018
    Zacks7 days ago

    Company News For Jun 13, 2018

    Companies In The News are: TSLA,SAGE,RH,PLAY

  • Here's Why Sage Therapeutics Rose as Much as 20.3% Today
    Motley Fool8 days ago

    Here's Why Sage Therapeutics Rose as Much as 20.3% Today

    The FDA approved an accelerated path through the clinic for the biopharma's next major drug candidate.

  • Is Sage Therapeutics Inc’s (NASDAQ:SAGE) Liquidity Good Enough?
    Simply Wall St.8 days ago

    Is Sage Therapeutics Inc’s (NASDAQ:SAGE) Liquidity Good Enough?

    Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Sage Therapeutics Inc (NASDAQ:SAGE), with a market capitalization of US$6.92B, rarely draw their attention from the investingRead More...

  • Why Tesla, Sage Therapeutics, and Lands' End Jumped Today
    Motley Fool8 days ago

    Why Tesla, Sage Therapeutics, and Lands' End Jumped Today

    Find out which of these stocks made the biggest move higher.

  • Why This Biotech Company Is Bounding Closer To A Breakout
    Investor's Business Daily8 days ago

    Why This Biotech Company Is Bounding Closer To A Breakout

    Sage Therapeutics bounded closer to a break out Tuesday after the biotech company outlined its expedited path to approval for a depression treatment.

  • Sage Therapeutics Rises After Depression Study Moves to Fast Lane
    Bloomberg8 days ago

    Sage Therapeutics Rises After Depression Study Moves to Fast Lane

    Sage Therapeutics Inc. climbed the most in two months after the U.S. Food and Drug Administration approved an expedited development plan for what the company says could be a practice-changing depression treatment. The biotechnology company only has to run a single 450-patient trial, which will allow for a compact, reasonably cost-efficient program that can assure both safety and effectiveness, Chief Executive Officer Jeff Jonas said in an interview. The medicine, SAGE-217, and the study design are different from those that have haunted psychiatric drugs in the past, according to Jonas.

  • Sage shares surge 15% after FDA OKs expedited depression drug development
    CNBC8 days ago

    Sage shares surge 15% after FDA OKs expedited depression drug development

    Sage Therapeutics says the FDA has cleared it to expedite development of its drug to treat major depressive disorder and postpartum depression.

  • MarketWatch8 days ago

    Sage shares surge 4.5% on plan to expedite drug development for two types of depression

    Sage Therapeutics Inc. shares surged 4.5% in premarket trade Tuesday on news that the company met with the Food and Drug Administration and now plans to expedite development of its SAGE-217 drug in two areas of depression, major depressive disorder and postpartum depression. Sage plans one new phase 3 trial in major depressive disorder, which will likely begin in the second half of this year, to support a FDA filing for the indication. It also plans to use an ongoing trial for postpartum depression, for which early results are expected in the fourth quarter, to support another filing.

  • Business Wire8 days ago

    Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced its expedited development plan for SAGE-217 following a Breakthrough Therapy meeting with the U.S. Food and Drug Administration (FDA). This development plan is intended to support a potential filing for approval of SAGE-217 in the U.S. for the treatment of major depressive disorder (MDD) and postpartum depression (PPD). The expedited development plan for SAGE-217 includes a single additional placebo-controlled Phase 3 pivotal trial in patients with MDD and the ongoing placebo-controlled trial in women with PPD, now designated a pivotal trial.

  • Business Wire12 days ago

    Sage Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference

    Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018 at 9:20 A.M.

  • Business Wire16 days ago

    Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on June 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 59,600 shares of its common stock to eleven new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

  • Sage’s Brexanolone IV: FDA Grants Priority Review
    Market Realist20 days ago

    Sage’s Brexanolone IV: FDA Grants Priority Review

    Sage Therapeutics (SAGE) is a US-based clinical-stage biopharmaceutical company. On May 30, Sage Therapeutics announced that the FDA accepted the new drug application for Brexanolone IV. The FDA granted a priority review for the drug. Following the news, the stock price increased ~1.8% to the closing price of $154.54 on May 30.

  • Business Wire21 days ago

    Sage Therapeutics Announces FDA Acceptance of NDA Filing and Grant of Priority Review for Brexanolone IV in the Treatment of Postpartum Depression

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for Sage’s lead product candidate, an intravenous formulation of brexanolone (SAGE-547) for the treatment of postpartum depression (PPD). The NDA was granted Priority Review status and the FDA assigned a Prescription Drug User Fee Act (PDUFA) target date of December 19, 2018. As expected for a new molecular entity with a new mechanism of action, the FDA is currently planning to hold an advisory committee meeting to discuss the brexanolone IV application.

  • Here's Why Marinus Pharmaceuticals Rose as Much as 18.4% Today
    Motley Fool27 days ago

    Here's Why Marinus Pharmaceuticals Rose as Much as 18.4% Today

    The tiny biopharma is back on the upswing following an analyst upgrade.

  • Business Wire28 days ago

    Sage Therapeutics to Present at Bernstein’s 34th Annual Strategic Decisions Conference

    Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at Bernstein’s 34th Annual Strategic Decisions Conference on Wednesday, May 30, 2018 at 11:00 A.M.

  • Why Wall Street Analysts Are Mostly Positive on CRISPR
    Market Realistlast month

    Why Wall Street Analysts Are Mostly Positive on CRISPR

    In December 2017, CRISPR Therapeutics (CRSP) entered a collaboration with Vertex Pharmaceuticals (VRTX) for the co-development and co-commercialization of CTX001. CRISPR Therapeutics submitted a CTA (clinical trial application) for CTX001 for the initiation of phase 1/2 trial for the evaluation of the safety and efficacy in the treatment of beta-thalassemia in Europe. CRISPR Therapeutics plans to submit an Investigational New Drug application to the FDA for the approval of an initiation of phase 1/2 clinical trial in the US for the treatment of sickle cell disease in the second half of 2018.

  • Business Wirelast month

    Sage Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference

    Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that members of the Sage management team will participate in a fireside chat presentation at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018 at 3:40 P.M.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes